ENESTcmr 36-Month Follow-Up: Deep Molecular Responses After Switching to Nilotinib in CML-CP


ENESTcmr 36-Month Follow-Up: Deep Molecular Responses After Switching to Nilotinib in CML-CP
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/24/14)
Leber B et al. Achievement and maintenance of deeper molecular response by switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib: ENESTcmr 36-month follow-up. Proc ASH 2013;Abstract 94.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.